Massimo Zecchin

Massimo Zecchin

Auto-generated profile, based on publicly available information

Massimo Zecchin

University Hospital of Trieste

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2013 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
MMMarco Merlo
Marco Merlo
APAlberto Pivetta
Alberto Pivetta
BPBruno Pinamonti
Bruno Pinamonti
DSDavide Stolfo
Davide Stolfo
MZMassimo Zecchin
Massimo Zecchin
GSGianfranco Sinagra
Gianfranco Sinagra
Aims ACE-inhibitors, β-blockers, implantable cardioverter–defibrillator (ICD) and cardiac resynchronization therapy (CRT) improved prognosis of heart failure. We sought to analyse the long-term prognostic impact of evidence-based integrated therapeutic strategies in patients with idiopathic dilated cardiomyopathy (IDCM). Methods and results From 1978 to 2007, 853 IDCM patients (45 ± 15 years, 72% males) were enrolled and classified as follows: Group 1, 110 patients (12.8%) enrolled during 1978–1987; Group 2, 376 patients (44.1%) enrolled during 1988–1997; Group 3, 367 patients (43.1%) enrolled during 1998–2007. ACE-inhibitors/angiotensin receptor blockers were administered in 34%, 93%, and 93% (P <0.001), and β-blockers in 11%, 82%, and 86% (P <0.001) in Groups 1, 2, and 3, respectively; ICDs were implanted in 2%, 14%, and 13% (P = 0.005); mean time to device implantation was lower in Group 3. At 8 years, heart transplant (HTx)-free survival rates were 55%, 71%, and 87% in Groups 1, 2, and 3, respectively (P <0.001). Similar progressive improvement was found for pump-failure death (DHF)/HTx, while survival free from sudden death (SD) was significantly improved only in Group 3. Multivariable models considering competing risk indicated early diagnosis (i.e. a baseline less advanced disease stage) and tailored medical therapy (HR 0.44, CI 95% 0.19–0.98) as independent protectors against DHF/HTx. Concerning SD, lower left ventricular ejection fraction emerged as a predictor, while ICD was the only therapy with a protective role (HR 0.08, CI 95% 0.01–0.61). Treatment with digitalis emerged as a predictor of both DHF/HTx and SD. Conclusions An effective management and evidence-based integrated therapeutic approach progressively and significantly improved the long-term prognosis of IDCM during the last three decades.

1 March 1997 in JACC
Verified
Journal Article
Closed access
BPBruno Pinamonti
Bruno Pinamonti
MZMassimo Zecchin
Massimo Zecchin
ALAndrea Di Lenarda
Andrea Di Lenarda
Dario GregoriDario Gregori
Dario Gregori
GSGianfranco Sinagra
Gianfranco Sinagra
FCFulvio Camerini
Fulvio Camerini

31 May 2012 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
GMGiosuè Mascioli
Giosuè Mascioli
LPLuigi Padeletti
Luigi Padeletti
BSBiagio Sassone
Biagio Sassone
MZMassimo Zecchin
Massimo Zecchin
ELElena Lucca
Elena Lucca
GSGianfranco Sinagra
Gianfranco Sinagra

1 March 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
MZMassimo Zecchin
Massimo Zecchin
MSMara Severgnini
Mara Severgnini
Alba FiorentinoAlba Fiorentino
Alba Fiorentino
VMVincenzo Livio Malavasi
Vincenzo Livio Malavasi
LMLoris Menegotti
Loris Menegotti
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani

1 March 2012 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MZMassimo Zecchin
Massimo Zecchin
MMMarco Merlo
Marco Merlo
APAlberto Pivetta
Alberto Pivetta
GBGiulia Barbati
Giulia Barbati
CLCristina Lutman
Cristina Lutman
GSGianfranco Sinagra
Gianfranco Sinagra

18 February 2014 in EP Europace
Verified
Journal Article
Open access
PDF file
Aneta AleksovaAneta Aleksova
Aneta Aleksova
CCCosimo Carriere
Cosimo Carriere
MZMassimo Zecchin
Massimo Zecchin
GBGiulia Barbati
Giulia Barbati
GVGiancarlo Vitrella
Giancarlo Vitrella
GSGianfranco Sinagra
Gianfranco Sinagra
Left bundle branch block (LBBB) is commonly associated with heart failure. We evaluated the prevalence, incidence, and impact of LBBB on long-term outcome in young patients with heart failure affected by idiopathic dilated cardiomyopathy (DCM). We included 608 patients with DCM from the Heart Muscle Disease Registry of Trieste in this retrospective analysis. At baseline electrocardiogram (ECG), 189 patients (31.1%) had LBBB. The patients with baseline LBBB had a significantly higher mortality rate than the patients without LBBB (38.6 vs. 27.9%, P = 0.002) at the univariate analysis. After a multiple covariate adjustment, the baseline LBBB was not associated with a significantly increased risk of death [hazard ratio (HR) 1.27, 95% confidence interval (CI): 0.88–1.81, P = 0.2]. Forty-seven (11.2%) patients without LBBB at baseline ECG developed LBBB during follow-up. Among these, the mortality rate was 49 vs. 25% in patients without new-onset LBBB (P = 0.001). New-onset LBBB was a strong and independent predictor of all-cause mortality (HR 3.18, 95% CI: 1.90–5.31, P < 0.001) at multivariate analysis. After correcting for potential confounders, new-onset LBBB was found to be associated with an increased risk of all-cause mortality. The management of patients with new-onset LBBB may need to be more aggressive, possibly including early cardiac resynchronization therapy/implantable cardioverter-defibrillator therapy.